Surrozen (NASDAQ:SRZN) and Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Comparison

Vigil Neuroscience (NASDAQ:VIGL) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Valuation and Earnings

This table compares Vigil Neuroscience and Surrozen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vigil Neuroscience	N/A	N/A	-$82.64 million	($2.06)	-1.12
Surrozen	$12.50 million	2.78	-$43.04 million	N/A	N/A

Surrozen has higher revenue and earnings than Vigil Neuroscience.

Volatility & Risk

Vigil Neuroscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Vigil Neuroscience and Surrozen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vigil Neuroscience	1	0	5	0	2.67
Surrozen	0	0	0	0	0.00

Vigil Neuroscience presently has a consensus target price of $16.60, suggesting a potential upside of 618.61%. Given Vigil Neuroscience’s stronger consensus rating and higher probable upside, equities analysts plainly believe Vigil Neuroscience is more favorable than Surrozen.

Insider & Institutional Ownership

83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 33.0% of Vigil Neuroscience shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vigil Neuroscience and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vigil Neuroscience	N/A	-83.89%	-65.34%
Surrozen	N/A	-120.51%	-54.68%

Summary

Vigil Neuroscience beats Surrozen on 6 of the 10 factors compared between the two stocks.

About Vigil Neuroscience

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.